Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses
Journal of Nuclear Medicine · 2026-11 · 67 (11) · 1855-1856
DOI: 10.2967/jnumed.126.272999 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 03.09.2026. Verfasst von Kyle Flannery und 2 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
TO THE EDITOR: We read with interest the recent publication by Gogebakan et al. ([1][1]) evaluating the cost-effectiveness of 177Lu-PSMA-617 versus cabazitaxel from a U.S. health care perspective. We commend the authors for addressing a relevant health economic question. We agree with their
Zitieren
APA
Flannery, K., Cavanaugh, P. F., & Steele, K. (2026). Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses. Journal of Nuclear Medicine, 67(11), 1855-1856. https://doi.org/10.2967/jnumed.126.272999
Vancouver
Flannery K, Cavanaugh PF, Steele K. Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses. Journal of Nuclear Medicine. 2026;67(11):1855-1856. doi:10.2967/jnumed.126.272999
BibTeX
@article{Flannery2026,
author = {Flannery, Kyle and Cavanaugh, Paul F and Steele, Kevin},
title = {Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {11},
pages = {1855--1856},
doi = {10.2967/jnumed.126.272999}
}
EUVIMED